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Strong evidence implicates cyclin D1 overexpression as 
a driving force in breast cancer and many other types of 
human tumors. Cyclin D1 overexpression is found in up 
to 50% of human breast cancers, and the pattern of 
cyclin D1 overexpression in tissues along the spectrum 
from normal epithelium to invasive breast cancer 
suggests its involvement in the earliest stages of 
mammary carcinogenesis. The importance of cyclin D1 
as a driver oncogene is reinforced by the frequent clonal 
selection of cyclin D1 gene amplification, found in 15-
20% of breast cancers, associated with poor prognosis, 
and by the fact that tissue-specific overexpression of 
cyclin D1 in transgenic mice results in mammary 
hyperplasia and adenocarcinoma [1].  However, the 
precise mechanisms through which cyclin D1 
overexpression contributes to breast tumorigenesis have 
been controversial. Specifically, while cyclin D1's role 
in the pathogenesis of breast cancer may well involve, 
at least in part, the well-established binding/activation 
of its catalytic partner kinases CDK4/6, with subsequent 
hyperphosphorylation of pRB and G1-S cell cycle 
transition, several lines of evidence have suggested that 
cyclin D1, especially when overexpressed in the setting 
of cancer, may also act through other, CDK-
independent, mechanisms. These alternative 
mechanisms of cyclin D1 action carry tremendous 
potential significance, for example in the rational 
targeting of new therapeutic agents. Our recent study 
[2] is perhaps the most direct test of this hypothesis 
performed in a highly relevant in vivo model system. 
The induction of chromosomal instability is known to 
promote genetic rearrangements, tumorigenesis and the 
molecular genetic chaos associated with poor outcome 
cancers. The early drivers to chromosomal instability 
are poorly understood. Our recent studies showed that 
modest overexpression of cyclin D1 is sufficient for the 
induction of chromosomal instability within 3 cell 
divisions, both in vitro and in vivo. Furthermore we 
showed the induction of CIN occurred independently of 
the kinase function. In ChIP-Seq cyclin D1 associates 
with genes governing chromosomal instability (CIN) 
[3]. Using a kinase dead mutant of cyclin D1 (cyclin 
D1KE ) we showed cyclin D1 induced - mitotic spindle 
architecture changes of chromosomal instability and 
supernumerary centrosomes aneuploidy and other 
features of CIN. In cdk4/6-/- 3T3 cells  cyclin  D1WT and  
 
 
                                                                      Editorial 
 
 
 
 
 
 
cyclin D1KE induced aneuploidy to a similar degree 
compared to control cells. Cyclin D1KE induced 
aneuploidy to a similar extent in absence or presence of 
cdk4/6 agonist. Crucially, sustained transgenic 
expression of cyclin D1KE induced mammary 
adenocarcinoma with similar kinetics to that of a cyclin 
D1WT transgene [1]. ChIP-Seq studies demonstrated 
recruitment in the context of local chromatin of either 
cyclin D1KE or cyclin D1WT to the genes governing 
CIN. Thus, cdk-activating function of cyclin D1 was not 
necessary for the induction of either chromosomal 
instability or murine mammary tumorigenesis. 
Understanding the different contexts and causes of 
cyclin D1 overexpression in breast cancer may be 
exceedingly important in considering its tumorigenic 
mechanisms. In this regard cyclin D1 knockout mice are 
resistant to breast cancer, however recent studies have 
shown that cyclin D1 genetic deletion abrogates the 
formation of progenitor cells that in turn give rise to 
cancer. Cyclin D1-/-KE rescue mice are resistant to ErbB2 
mediated tumorigenesis [4]. Elegant studies by Hinds’ 
group identified a progenitor population of cells in 
mouse mammary gland (parity-identified mammary 
cells: PI-MEC) that require cyclin D1 kinase activity for 
self renewal and differentiation [5]. An analysis on the 
cyclin D1-/- KE rescue confirmed that the resistance to 
ErbB2 driven tumorigenesis is linked to near total 
absence of the PI-MEC, making those progenitor cells 
the likely target for ErbB2 induced tumorigenesis. 
Cyclin D1 kinase activity is therefore required for 
mammary progenitor cells self-renewal and activity, 
highlighting this key role for cyclin D1 during 
development. In contrast, our recent study of mice 
bearing the MMTV-cyclin D1KE transgene addressed 
whether cyclin D1 overexpression can directly induce 
mammary tumorigenesis in a kinase independent 
manner, with a robust answer of ‘yes’. 
The MMTV-ErbB2 and MMTV-cyclin D1 models are 
distinct. MMTV-ErbB2 induced mouse tumorigenesis 
represents a good model for human breast cancers with 
HER2 amplification, and the role of cyclinD1 when 
expressed secondary/downstream to other events (like 
ErbB2 amplification) may well be kinase dependent. In 
contrast, MMTV-cyclin D1 mice better represent the 
sizeable group of cyclin D1-amplified cancers, induced 
by primary, driver-level overexpression of the cyclin D1 
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oncogene. Cyclin D1 oncogene activation is a prevalent 
molecular driver of human cancer, playing key roles in 
breast, squamous cell, esophageal carcinoma, mantle 
cell lymphoma, multiple myeloma, and many other 
devastating human malignancies. Our novel in vivo 
evidence shows this mechanism can be kinase-
independent, counter to the generally accepted “CDK-
centric” paradigm of the tumorigenic activity of cyclin 
D1. In the clinical realm, these observations suggest that 
some therapeutic agents now approved or in 
development, most notably CDK4/6 inhibitors, will 
have limited efficacy in cyclin D1-amplified cancers 
since they target only the kinase partners of cyclin D1. 
Thus, without minimizing the improved progression-
free survival associated with pharmacologic CDK4/6 
inhibition in ER+ breast cancers, our data suggest that 
in the subset of tumors with, and potentially addicted to, 
cyclin D1 amplification or rearrangement, a more 
effective path to impactful tumor shrinkage as opposed 
to slowing of growth will be to develop agents that 
target cyclin D1 directly.  In summary, while cyclin D1 
kinase activity is important in tumorigenesis, additional 
distinct kinase-independent mechanisms, including 
induction of chromosomal instability, are helping drive 
some tumors and attempts to exploit this finding using 
precision medicine should be encouraged. 
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